Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 MonthsThe Motley Fool • 09/26/26
2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.The Motley Fool • 09/20/26
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive DirectorsGlobeNewsWire • 09/17/26
argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/14/26
BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug DiscoveryBusiness Wire • 09/02/26
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?The Motley Fool • 09/02/26
Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger StoryThe Motley Fool • 08/26/26
ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock UpZacks Investment Research • 08/18/26
argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis TranscriptSeeking Alpha • 08/18/26
Argenx Breaks Out On Another Multibillion-Dollar Opportunity For VyvgartInvestors Business Daily • 08/17/26
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune MyositisBusiness Wire • 08/17/26
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune MyositisGlobeNewsWire • 08/17/26
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRXBusiness Wire • 08/11/26
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.GlobeNewsWire • 08/06/26
argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026GlobeNewsWire • 08/03/26
A portfolio manager says investors are looking overseas as Magnificent Seven worries grow. Here are the stocks and sectors he favorsCNBC • 07/31/26